Telo Genomics Corp (TELO) AI Stock Analysis

• Market Cap: C$5.02M
• Dividend Yield: N/A
• Average Volume (3M): 29.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: N/A
• EPS Growth: 19.05%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 100,430,470
• 10 Day Avg. Volume: 22,350
• 30 Day Avg. Volume: 29,304
• PEG Ratio: 0.19
• Price to Book (P/B): 18.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.05 ▲(32.50% Upside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is held down primarily by weak financial performance (pre-revenue, persistent losses, and cash burn with negative equity), with technicals also indicating a broader downtrend. Corporate events provide some positive clinical/validation progress, but valuation remains constrained by ongoing losses and no dividend support.

Positive Factors

Proprietary Telomere Platform

Telo’s single-chromosome telomere measurement is a differentiated, proprietary technology that creates a structural barrier to entry. Over the medium term this core IP supports clinical partnerships, licensing opportunities and product-led commercialization if validation converts to adoption.

Low Leverage

Reported zero debt reduces solvency and interest obligations, giving management flexibility to prioritize R&D and validation spending. In a capital-intensive biotech phase, low leverage preserves optionality to raise equity or negotiate partnerships without debt servicing constraints.

Clinical/Validation Momentum

Multi-center validation and MRD presentations build the clinical evidence base crucial for diagnostic adoption. Sustained validation programs improve prospects for regulatory acceptance, reimbursement and institutional partnerships, materially improving commercialization odds over months.

Negative Factors

Pre-Revenue Status

The company remains pre-revenue, so commercial demand and product-market fit are unproven. Without recurring sales or licensing, the business must convert validation into customers; failure or delay raises execution risk and prolongs reliance on external capital.

Persistent Cash Burn

Operating cash flow of roughly -$2.16M TTM and negative free cash flow signal ongoing burn. Continued cash deficits force fundraising, increasing dilution risk and potentially constraining R&D, validation scale-up, or commercialization investments absent near-term revenue or financing.

Negative Equity

A shift to slightly negative stockholders’ equity reflects accumulated losses and likely dilution. Negative equity weakens the balance sheet, limits financing alternatives, and raises counterparty concerns, increasing structural capital risk during the commercialization ramp.

Telo Genomics Corp Business Overview & Revenue Model

Company Description

Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.

How the Company Makes Money

Telo Genomics Corp generates revenue primarily through the commercialization of its genomic testing products and services. The company offers diagnostic tests that are used in clinical settings to aid in the detection and monitoring of diseases. Revenue streams include sales of test kits, laboratory services, and potentially licensing agreements for its proprietary technologies. Partnerships with healthcare providers, research institutions, and pharmaceutical companies are significant contributors to its earnings, allowing for broader distribution and integration of its genomic solutions into medical practice.

Telo Genomics Corp Financial Statement Overview

Summary

Very weak fundamentals: the company is pre-revenue with large, persistent losses and continued operating/free-cash-flow burn. Low/no debt helps, but the shift to slightly negative equity in TTM and ongoing funding needs materially increase financial risk.

Income Statement

The company is still pre-revenue (revenue is 0 across the periods provided), while losses remain large and persistent. Net loss is roughly $2.7M in TTM (Trailing-Twelve-Months) and has not shown sustained improvement versus prior years, indicating the business has yet to demonstrate operating leverage. A modest positive is that losses are not dramatically accelerating versus the last few annual periods, but overall profitability and revenue traction are the key weaknesses.

Balance Sheet

Leverage is low with total debt at 0 in the most recent periods (and minimal historically), which reduces solvency risk from creditors. However, the balance sheet weakened materially: stockholders’ equity moved from positive levels in prior annual reports to slightly negative in TTM (Trailing-Twelve-Months), a significant red flag that suggests dilution and/or accumulated losses have eroded the capital base. Total assets also declined from prior years, reducing financial flexibility.

Cash Flow

Cash burn remains heavy, with operating cash flow around -$2.16M in TTM (Trailing-Twelve-Months) and free cash flow similarly negative. While burn improved versus some earlier annual periods, the latest free cash flow growth is sharply negative, highlighting volatility and ongoing funding needs. A relative positive is that free cash flow closely tracks net income (losses are largely cash-based rather than being masked by large non-cash gains), but the business still lacks self-funding capacity.

Breakdown	Sep 2025	Sep 2023	Jun 2022	Sep 2020	Jun 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-14.45K	-39.54K	-33.11K	-62.23K	-64.72K
EBITDA	-2.69M	-2.67M	-2.78M	-1.01M	-1.15M
Net Income	-2.72M	-2.71M	-2.82M	-1.07M	-1.24M
Balance Sheet
Total Assets	911.30K	965.64K	2.93M	3.84M	1.17M
Cash, Cash Equivalents and Short-Term Investments	789.29K	796.02K	2.67M	3.64M	920.98K
Total Debt	0.00	0.00	32.50K	40.00K	40.00K
Total Liabilities	396.32K	375.59K	312.87K	153.66K	393.42K
Stockholders Equity	514.98K	590.06K	2.61M	3.69M	775.25K
Cash Flow
Free Cash Flow	-2.33M	-2.46M	-2.70M	-1.11M	-1.13M
Operating Cash Flow	-2.33M	-2.46M	-2.63M	-1.10M	-1.12M
Investing Cash Flow	-3.25K	-5.12K	-69.06K	-9.31K	-8.67K
Financing Cash Flow	2.33M	587.05K	2.68M	3.83M	2.03M

Telo Genomics Corp Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELO, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.06 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:TELO.

Telo Genomics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BUX	50 Neutral	C$67.26M	-39.51	―	―	-21.89%	26.36%
AVCR	47 Neutral	C$7.09M	-4.35	-71.97%	―	-59.28%	-1563.64%
TELO	44 Neutral	C$5.02M	-1.73	-9999.00%	―	―	19.05%
SONA	41 Neutral	C$40.68M	-12.29	-2846.90%	―	―	10.97%
KNE	41 Neutral	C$6.36M	-2.87	―	―	―	―

Telo Genomics Corp Corporate Events

Telo Genomics Raises $840,000 in First Tranche of Convertible Debenture Financing

Telo Genomics Corp. has closed the first tranche of a non-brokered private placement of secured convertible debentures, raising gross proceeds of $840,000. The debentures carry 15% annual interest, mature on December 15, 2026, and are convertible into common shares at $0.05 per share, with investors also receiving warrants exercisable at $0.08 per share.

The company plans to use the funds to support lab trials and general working capital, incurring cash finder’s fees and issuing additional finder’s warrants as part of the financing. The offering remains subject to TSX Venture Exchange approval, and all securities issued in this first tranche are subject to a four-month-plus-one-day hold period under Canadian securities laws.

The most recent analyst rating on (TSE:TELO) stock is a Sell with a C$0.04 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.

Telo Genomics Strengthens Finance Team With Appointment of Veteran CFO John Price

Telo Genomics Corp. has appointed John Price as its new Chief Financial Officer, effective January 30, 2026, bringing more than 30 years of experience in accounting operations, financial planning, M&A and capital markets, including executive roles at several public companies and finance positions in high-growth Silicon Valley technology firms. Price’s arrival, succeeding outgoing CFO Christopher Ross, signals a strengthening of Telo Genomics’ financial leadership as the company advances its telomere-based liquid biopsy and prognostic platforms, potentially enhancing its ability to navigate capital markets, support commercialization of its lead multiple myeloma application and bolster its position within the rapidly expanding field of minimally invasive diagnostics.

The most recent analyst rating on (TSE:TELO) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.

Telo Genomics Seeks Up to $1.2 Million via Convertible Debenture Financing

Telo Genomics Corp. has launched a non-brokered private placement of secured convertible debentures to raise up to $1.2 million, offering 15% annual interest with a nine-month term and a conversion price of $0.05 per share, along with detachable warrants exercisable at $0.08 per share. The capital is earmarked for lab trials and general working capital, and the financing structure, which includes a four-month hold period and is contingent on TSX Venture Exchange approval, underscores the company’s need to fund ongoing clinical and product development efforts as it advances its telomere-based diagnostics platform toward broader commercialization.

The most recent analyst rating on (TSE:TELO) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.

Telo Genomics Expands Multiple Myeloma MRD Validation with University of Athens Study

Telo Genomics has launched a retrospective, blood-based multiple myeloma minimal residual disease study with the University of Athens as part of its 2026 multi-center validation program for its TeloView MRD assay. The trial will leverage well-characterized patient blood samples with several years of follow-up and existing next-generation flow MRD data from both blood and bone marrow to compare prognostic performance and relapse prediction, with Telo’s assay targeting greater sensitivity and additional insight through analysis of 3D genomic architecture. This initiative, alongside ongoing prospective trials with Cleveland Clinic and Jewish General Hospital and planned additional retrospective collaborations, is intended to build a robust clinical evidence base that could support broader clinical adoption of Telo’s blood-based MRD technology and strengthen its position in the rapidly expanding global MRD testing market for multiple myeloma.

Telo Genomics Unveils Innovative Myeloma Testing at ASH Meeting

Telo Genomics Corp. presented its innovative approach to Multiple Myeloma Minimal Residual Disease testing at the 67th American Society of Hematology Meeting. The company’s method combines enumeration of circulating tumor cells with 3D telomere profiling, offering insights into disease progression and reducing the need for invasive bone marrow procedures. This advancement aligns with the growing trend in personalized healthcare and the expanding MRD testing market, which is projected to reach USD 4.1 billion by 2032. The approach could significantly impact treatment strategies and drug approval processes in the oncology field, particularly for multiple myeloma, a challenging blood cancer with a substantial treatment cost and relapse rate.